Study exposes opportunities for strengthening cancer drugs trials in China
Of more than four hundred phase 2 and 3 randomized trials of cancer drugs registered in China between 2016 and 2017, about sixty had suboptimal control arms
2023-12-12
(Press-News.org) More than one-eighth of the randomized trials of cancer drugs seeking regulatory approval in China in recent years used inappropriate controls to test the effectiveness and safety of the drugs, according to a new study published December 12th in the open access journal PLOS Medicine by Professor Xiaodong Guan of Peking University, China, and colleagues.
In randomized trials, patients are assigned to either a control arm, in which they receive the current optimal treatment, or an experimental arm, in which they receive the new drug being tested. However, studies have previously found that control arms in cancer clinical trials (including in the United States) are not supported by relevant guidelines, instead using treatments other than the standard-of-care. Adopting a suboptimal control group may bias a study’s results in favor of the experimental arm, potentially exposing patients to substandard therapy and producing unreliable results of clinical efficacy.
In the new study, researchers analyzed the control arms of 453 Phase II/III and Phase III randomized oncology trials authorized by Chinese institutional review boards between 2016 and 2021, supporting investigational new drug applications of these drugs in China.
Overall, 60 trials (13.2%) used suboptimal control arms. Of those suboptimal trials, 35 (58.3%) used comparators that were not recommended by a prior guideline. In total, 18,610 people enrolled in clinical trials (15.1% of the total number in all samples trials) were exposed to suboptimal treatments due to the control arms. Trials using suboptimal controls were more likely to report a positive result for the experimental arm. In addition, the researchers found an overall upward trend in the number of trials using inappropriate control arms.
“Trial sponsors, ethical review boards, and oncologists should make collaborative efforts to protect patients from unnecessary harm and drugs with uncertain clinical benefits over the existing standard of care,” the authors say. “Regulatory agencies should be cautious when reviewing investigational new drug applications whose supporting trial used a suboptimal control.”
The authors add, “This research highlights the necessity to refine the design of randomized trials to generate optimal clinical evidence for new cancer therapies. In November 2021, China issued the Guidance on Clinical Value-Oriented Oncology Drug Research and Development, aiming to promote a better generation of clinically relevant novel oncology drugs in China. We hope our research findings can provide empirical evidence to the stakeholders and draw regulators’ attention to this matter so that the guideline can be delivered in the manner that it set out to be.”
#####
In your coverage, please use this URL to provide access to the freely available paper in PLOS Medicine: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004319
Citation: Zhang Y, Chen D, Cheng S, Liang Z, Yang L, Li Q, et al. (2023) Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016–2021: An observational study. PLoS Med 20(12): e1004319. https://doi.org/10.1371/journal.pmed.1004319
Author Countries: China
Funding: XG received the National Natural Science Foundation of China award (Grant No. 72274004, http://www.nsfc.gov.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
END
ELSE PRESS RELEASES FROM THIS DATE:
2023-12-12
MADISON – An interdisciplinary team led by University of Wisconsin–Madison scientists has developed a new technique that could help farmers extract useful nutrients such as ammonia and potassium from livestock manure to efficiently make fertilizer and other useful chemical products. While the strategy still needs to be scaled up beyond a proof-of-concept stage, the group's preliminary analyses show it could offer considerable benefits by cutting water and air pollution while simultaneously creating products that farmers could use or sell.
Manure stinks in part because it contains ammonia, one of the more ...
2023-12-12
DENVER/Dec. 12, 2023 – A new article published in the journal Methods in Ecology and Evolution by Morris Animal Foundation-funded researchers describes a simplified method to detect a deadly fungus killing European salamanders. The ability to rapidly find the fungus is significant as the disease, although not detected in the U.S., could impact the millions of amphibians and salamanders annually imported.
The fungal pathogen Batrachochytrium salamandrivorans, or Bsal, threatens salamander diversity. Initially identified in northern Europe, evidence suggests it was introduced from Southeast Asia via the pet trade.
“The impacts of Bsal ...
2023-12-12
EMBO launches a new award for laboratory sustainability: The EMBO Lab Sustainability Award will recognize new and significant contributions to the development of sustainable wet and dry labs with a focus on their environmental impact. The award will be presented to an individual representing the initiative or project. Applications can be submitted between 15 January and 15 March 2024.
The award winner will have the opportunity to present their initiative or project at scientific events and publish a commentary in EMBO Reports. In addition, the winning project will be supported with a grant of 10,000 euros. The award is one of ...
2023-12-12
ROCHESTER, Minn. — Stem cell-based therapy improved quality of life for patients with advanced heart failure, Mayo Clinic researchers and international collaborators discovered in a late-stage multinational clinical trial. In one of the largest studies of cell intervention after a heart attack, patients reported their daily hardship lessened when stem cells optimized for heart repair supplemented standard of care. This clinical study further documented lower death and hospitalization rates among those treated with cell therapy. This research ...
2023-12-12
ABSTRACT: LBA-2
SAN DIEGO ― The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III SYMPATICO trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.
At a median follow-up of 51.2 months, median PFS was 31.9 months with the combination compared to 22.1 months with ibrutinib plus placebo. PFS benefits were consistent across patient subgroups, including those with blastoid-variant ...
2023-12-12
DURHAM, N.C. – Identifying an older patient who is at risk for post-operative cognitive dysfunction might be done in the blink of an eye – literally.
Researchers at Duke Health found that a simple EEG measurement detects a signal of cognitive vulnerability when patients are asked to close, then open their eyes. Conducted prior to surgery, the non-invasive readout of brain waves helps predict which patients are at risk of post-operative confusion and attention problems.
“Roughly half of seemingly normal older adults experience problems with thinking, memory or attention after surgery,” said Leah Acker, M.D., Ph.D., assistant professor in ...
2023-12-12
In April 2015, looters sacked an ancient cave burial at a site called Urd Ulaan Uneet high within the Altai Mountains of western Mongolia. When police apprehended the criminals, they uncovered, among other artifacts, an elegantly carved saddle made from several pieces of birch wood.
Now, in a new study, researchers from Mongolia collaborating with University of Colorado Boulder archaeologist William Taylor have described the find. The team’s radiocarbon dating pins the artifact to roughly the 4th Century ...
2023-12-12
UNIVERSITY PARK, Pa. — Self-propelled nanoparticles could potentially advance drug delivery and lab-on-a-chip systems — but they are prone to go rogue with random, directionless movements. Now, an international team of researchers has developed an approach to rein in the synthetic particles.
Led by Igor Aronson, the Dorothy Foehr Huck and J. Lloyd Huck Chair Professor of Biomedical Engineering, Chemistry and Mathematics at Penn State, the team redesigned the nanoparticles into a propeller shape to better control their movements and increase their functionality. ...
2023-12-12
Karandeep Singh, MD, has been recruited as the Joan and Irwin Jacobs Endowed Chair in Digital Health Innovation at University of California School of Medicine and named as the inaugural chief health artificial intelligence (AI) officer at UC San Diego Health, a newly developed position for the region’s only academic medical center.
This new role will be effective December 29, 2023.
In this position, Singh will focus on implementing change that advances safety and health outcomes in acute and ambulatory settings. His contributions will be pivotal in bringing innovation to ...
2023-12-12
NEW YORK, NY--Many Black Americans who are thought to have a high risk of developing kidney disease possess a protective genetic variant that nullifies the extra risk, a new study from Columbia researchers has found.
The study found that high-risk people who carry this variant have a risk of developing kidney disease much closer to that of the general population.
The findings will have an immediate impact on clinical practice, says study leader Simone Sanna-Cherchi, MD, associate professor of medicine at Columbia’s Vagelos College of Physicians and Surgeons.
“Physicians ...
LAST 30 PRESS RELEASES:
[Press-News.org] Study exposes opportunities for strengthening cancer drugs trials in China
Of more than four hundred phase 2 and 3 randomized trials of cancer drugs registered in China between 2016 and 2017, about sixty had suboptimal control arms
